Want to see TSE:NEVI full AI Analyst Report?
NEVI Stock Chart & Stats
C$0.02
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.02
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.09
Previous CloseN/A
Volume20.00K
Average Volume (3M)27.36K
Market Cap
C$991.57K
Enterprise ValueC$1.32M
Total Cash (Recent Filing)C$60.85K
Total Debt (Recent Filing)C$394.63K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Oct 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding39,662,727
10 Day Avg. Volume4,232
30 Day Avg. Volume27,356
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.05
Price to Sales (P/S)1.17
P/FCF Ratio31.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Manageable LeverageModerate leverage and positive equity provide a more stable financial base than earlier periods when equity was negative. This reduces balance-sheet pressure and preserves some flexibility to fund operations, pursue development work, or withstand continued volatility while the company works toward profitability.
Recent Positive Cash FlowThe shift from negative operating and free cash flow in FY2023–FY2024 to positive TTM generation is an important improvement in internal funding capacity. Positive cash generation can reduce reliance on external financing, although its durability depends on stabilizing revenue and lowering operating losses.
Improved Gross MarginA materially higher gross margin indicates better economics on the company’s reported revenue base and creates greater potential for operating leverage if sales stabilize. The smaller EBITDA loss also suggests progress in cost absorption, though the business has not yet reached sustainable profitability.
Bears Say
Sharp Revenue ContractionA sharply contracting top line is a fundamental challenge because it limits scale benefits, weakens visibility into future demand, and makes fixed operating costs harder to absorb. Until revenue stabilizes or returns to growth, margin improvements may not translate into durable earnings or cash-flow expansion.
Persistent Operating LossesContinued net and operating losses show that the current business model is not yet generating adequate returns from its asset and equity base. Persistent losses can erode financial resources over time and constrain investment in research, development, and other activities needed to build lasting growth.
Modest And Shrinking Cash GenerationAlthough cash flow has recently turned positive, the decline versus the prior period and modest coverage relative to revenue indicate limited cash-generation strength. This makes the improvement less dependable over a two-to-six-month horizon and leaves performance sensitive to further revenue weakness or ongoing operating losses.
Pascal Biosciences Inc News
NEVI FAQ
What was Pascal Biosciences Inc’s price range in the past 12 months?
Pascal Biosciences Inc lowest stock price was C$0.01 and its highest was C$0.09 in the past 12 months.
What is Pascal Biosciences Inc’s market cap?
Pascal Biosciences Inc’s market cap is C$991.57K.
When is Pascal Biosciences Inc’s upcoming earnings report date?
Pascal Biosciences Inc’s upcoming earnings report date is Oct 16, 2026 which is in 3 days.
How were Pascal Biosciences Inc’s earnings last quarter?
Pascal Biosciences Inc released its earnings results on Jul 16, 2026. The company reported -C$0.002 earnings per share for the quarter.
Is Pascal Biosciences Inc overvalued?
According to Wall Street analysts Pascal Biosciences Inc’s price is currently Overvalued.
Does Pascal Biosciences Inc pay dividends?
Pascal Biosciences Inc does not currently pay dividends.
What is Pascal Biosciences Inc’s EPS estimate?
Pascal Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pascal Biosciences Inc have?
Pascal Biosciences Inc has 39,662,727 shares outstanding.
What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
Pascal Biosciences Inc reported an EPS of -C$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pascal Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:NEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pascal Biosciences Inc
Nevis Brands Inc. engages in the development and sale of cannabis products in the United States. It offers hemp derived THC beverages under the Major brand name. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevis Brands Inc. is headquartered in Seattle, Washington.
Technical Analysis
TAAT Global Alternatives
―
―
Modern Meat
―
Lifeist Wellness
―
Element Nutritional Sciences Inc
―